FN1 and non-small cell lung carcinoma: To further investigate the potential clinical value of integrin αvβ3 inhibitor-based combination therapy in relatively high malignant patients with NSCLC, we established an FN-treated NSCLC mouse model by instilling 2 × 106 FN-pretreated A549 cells through intratracheal instillation.